Biogen Plunges On Slashed Guidance; AbbVie Q2 Mixed

By | July 24, 2015

Scalper1 News

Big-cap biotech Biogen (BIIB) beat Q2 earnings estimates Friday, but it lowered its guidance and reported failure in a clinical trial, sending its stock plummeting. Meanwhile, big pharma AbbVie (ABBV) reported a steadier quarter and affirmed its guidance, but its stock was sliding after sales came up short. Biogen’s earnings, excluding one-time items, rose 21% over the year-earlier quarter to $4.22 a share, beating analysts’ consensus by 12 cents. Scalper1 News

Scalper1 News